MOORESTOWN, N.J., July 24, 2017 -- Tabula Rasa HealthCare (NASDAQ:TRHC) Chairman and CEO, Calvin H. Knowlton, PhD, was the keynote speaker at The American Society for Automation in Pharmacy (ASAP) MidYear Conference in Palm Beach, Florida on June 22, 2017. Knowlton addressed the issue of adverse drug events (ADEs) and how technology can provide solutions.
“Regarding adverse drug events, unintentional misuse and overdose is looming,” said Dr. Knowlton. “As pharmacists, we must collaborate with our software friends to provide us with the medication risk mitigation tools we need to effect change and eliminate ADEs, which are often cited as the fourth leading cause of death. It is time to integrate the science that underlies our medication safety metrics into our pharmacy technology and systems.”
The conference highlighted technology’s role in pharmacy, particularly regarding ADEs, regulatory and dispensing requirements, cybersecurity in healthcare, specialty pharmacy and more.
Dr. Knowlton is the Founder, Chairman and CEO of Tabula Rasa HealthCare (TRHC), a healthcare technology company optimizing medication safety by developing new Medication Risk Mitigation™ and medication decision support tools.
Dr. Knowlton has won numerous awards for his leadership in pharmacy, business, and philanthropy in his career of over 30 years, including the 2003 & 2013 Ernst and Young Entrepreneur of the Year Award, Greater Philadelphia Region, and the 2016 Philadelphia Technology CEO of the year. In 2015, Knowlton was awarded the Remington Honor Medal, pharmacy’s highest honor.
Contributing to his profession and the community, Dr. Knowlton has served as the national President for the American College of Apothecaries, President of the American Pharmacists Association (APhA) for two terms, and President of the American Pharmacists Association Foundation. He is the Board Chair of the Evergreens Continuing Care Retirement Community and serves on the Boards of Cooper Medical School of Rowan University. He recently finished terms on the Coriell Institute for Medical Research, St Christopher’s Hospital for Children in Philadelphia and the Settlement Music School in Philadelphia, PA.
Dr. Knowlton received his Pharmacy degree from Temple University, his Divinity degree from Princeton Theological Seminary, and his PhD in Pharmacoeconomics from the University of Maryland. He served as Professor and Department Chair for the University of the Sciences in Philadelphia in the 1990s. He has authored and co-authored textbooks, book chapters, and articles focused on the role and responsibility of pharmacists in the outcomes of patient-centered medication care.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s leading offering, and its cloud-based software applications, including EireneRx® and MedWise Advisor®, provide solutions for a range of payers, providers and other healthcare organizations. www.tabularasahealthcare.com
Contact Dianne Semingson [email protected] T: 215-870-0829


Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
First Western Ship Transits Strait of Hormuz Since Iran War Began
Apple Turns 50: From Garage Startup to AI Crossroads
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 



